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rosis-related diseases.
Methods

Animals and Treatment
Twenty male wild-type C57BL/6J mice and 40 male apoE-/-mice on a C57BL/6J background were purchased from Model Animal Research Center of Nanjing University (Nanjing, China) at 6 weeks of age. Animal experiments were conducted under the Guidelines for Animal Experimentation of China Pharmaceutical University (Nanjing, China) and protocols were approved by the Animal Ethics Committee of this institution. After 2 weeks of acclimatization, the apoE-/-mice were randomly divided into 2 groups (n=20 each). Mice in the control group were fed a Western-type diet containing 21% fat, 0.15% cholesterol (Qinglongshan, Nanjing, China) for 12 weeks. The treatment group (CRA group) received the same diet but with a CRA (0.3 mg · day -1 · mouse -1 ) supplement. CRA was isolated from the aerial parts of S. miltirrhiza Bunge (purity >95%) and dosages were chosen according to the previous study. 2 Wild-type C57BL/6J mice (wild-type group) were fed a regular chow diet as a blank control.
Tissue Preparation and Assessment of Atherosclerotic Lesions
At the end of the experiment, mice were anesthetized using sodium pentobarbital and fasting blood was drawn by eyeball removal. Serum was separated and stored at -70°C for further analysis. Aortas were prepared as previously described. 12 In brief, after perfusion with phosphate buffered saline (PBS; pH 7.4) containing ethylenediaminetetraacetic acid (2 mmol/L) and butylated hydroxytoluene butylated hydroxytoluene (BHT) (20 μmol/L), the dissected entire aorta was placed in PBS, and the adventitia was removed in situ under the dissecting microscope as far as possible. The cross-sections of the aortic valve were used for morphometry and immunohistochemistry. Paraffin sections were prepared according to the method described previously. 13, 14 In brief, the tissue was embedded in paraffin and serial 5-μm-thick sections were transversally cut from the origin of the aortic valve leaflets, throughout the aortic sinus. The extent of atherosclerosis was determined using morphometric analysis and a quantification method. For morphometric analysis, the paraffin sections of the aortic valve were used. Sections were observed under a light microscope (Olympus, Tokyo, Japan) after staining with hematoxylin and eosin (H&E; Sunshine Biotechnology, Nanjing, China). The average of at least 5 slides per mouse was used for analysis. Percent lesion area was calculated using Image-Pro Plus (version 6.0; Media Cybernetics, Bethesda, MD, USA). For quantification of the lesion area, the entire aorta from the heart, extending to the iliac arteries and including the subclavian right and left common carotid arteries, was removed and cut longitudinally and flattened on a smooth surface to expose the intimal surface. Then the aortic arch and abdominal aorta were fixed with formal-sucrose for 12 h, and lipids were stained with Sudan IV (Sigma Chemical, St Louis, MO, USA). The aortic arch was defined as the region from the ascending arch to 3 mm distal of the subclavian artery. 13 Images were taken with a digital camera (Canon 500D, Tokyo, Japan). Mean lesion area was calculated from the digital images obtained from 6-8 samples, using Image-Pro Plus.
Serum Profiles
Serum concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), LDLcholesterol (LDL-C), glucose, superoxide dismutase (SOD), and malondialdehyde (MDA) were assayed spectrophotometrically using commercial kits (Jiancheng Bio Company, Nanjing, China) following the manufacturer's protocols.
MCP-1 Enzyme-Linked Immunosorbent Assay (ELISA)
One centimeter of the thoracic aortas was cut into small segments and incubated in serum-free medium at 37°C overnight while gently being shaken. Supernatants were then collected. MCP-1 levels in the supernatant and serum samples were determined on sandwich ELISA using commercial kits specific for mouse MCP-1 (R&D system, Minneapolis, MN, USA) following the manufacturer's protocols.
Quantitative Polymerase Chain Reaction
Total RNA was extracted from the entire aorta using Trizol reagent (Invitrogen, Carlsbad, CA, USA) to determine the mRNA expression of MCP-1 and CCR2. cDNAs were synthesized using PrimeScript Reverse Transcriptase (TaKaRa Bio, Otsu, Japan) and random primers. The resulting cDNAs were amplified using SYBER Green PCR kit (Applied Biosystems, Foster City, CA, USA). Quantitative polymerase chain reaction (PCR) was performed on an ABI PRISM 7500 sequence detection system (Applied Biosystems). PCR primers were as follows: β-actin: forward, 5'-GTGCTATGTTGCTCTAGA-CTTCG-3'; reverse, 5'-ATGCCACAGGATTCCATACC-3'; MCP-1: forward, 5'-GCCTGCTGTTCACAGTTGC-3'; reverse, 5'-GGTGATCCTCTTGTAGCTCTCC-3'; and CCR2: forward, 5'-TGTGCTAAGAATTGAACTTGAATC-3'; reverse, 5'-AAGGCTCACCATCATCGTAGT-3'. Samples were assayed in triplicate and the relative abundance of mRNAs was calculated with the ΔΔCT method 15 with β-actin mRNA as the invariant control.
Immunohistochemistry
The paraffin sections of the aortic valve (5 μm) were used for immunohistochemistry staining. Sections were analyzed using standard procedures as follows: sections were deparaffinized and rehydrated; slides were immersed in 10 mmol/L citrate buffer (pH 6.0) and boiled for 10 min to retrieve the antigen; endogenous peroxidase was blocked with 0.3% H2O2 for 10 min; the non-specific binding sites were blocked with 5% normal goat serum for 10 min, then the slides were incubated with primary antibodies for 1 h at room temperature; immunoreactivity was visualized using peroxidase-DAB. Primary antibodies included the following: monoclonal antibody (mAb) anti-mouse MCP-1 antibody diluted 1:50, mAb anti-mouse CCR2 antibody diluted 1:50, mAb anti-mouse interleukin (IL)-8 antibody diluted 1:50; mAb anti-mouse intercellular adhe- Figure 1 . Chemical structure of corosolic acid (2α,3β-dihydroxy-urs-12-en-28-oic acid). Anti-Atherogenic Effects of Corosolic Acid sion molecule (ICAM)-1 antibody diluted 1:100; mAb antimouse NF-κB p65 (Phospho-Ser276) antibody diluted 1:20. All antibodies were purchased from Abcam (Cambridge, UK). Images were captured using a Carl Zeiss inverted microscope and analyzed using Image-Pro Plus (version 6.0, Media Cybernetics, Bethesda, MD, USA). Five locations were randomly harvested per slide. The average of at least 5 slides of each group was used for analysis.
Cell Culture and Treatment
The human monocyte cell line THP-1 was purchased from the Cell Bank of Shanghai Institute of Cell Biology (Shanghai, China). THP-1 cells were maintained in RPMI1640 (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (PAA Laboratories, Parshing, Austria), and cultured at 37°C in a humidified atmosphere containing 5% CO2. CRA was prepared in sterilized dimethyl-sulfoxide (DMSO; Sigma Chemical) and stored at 4°C. Cultured cells were pretreated with CRA at final concentrations of 0, 10, 30, and 50 μmol/L in serum-free medium and incubated for 24 h. To initiate an inflammatory response, cells were stimulated with 10 μg/ml lipopolysaccharide (LPS; E. coli O55: B5, Sigma Chemical) for 3 h.
Semiquantitative Polymerase Chain Reaction
Total RNA was extracted from 1×10 6 treated THP-1 cells using Trizol reagent (Invitrogen) to measure mRNA expression of MCP-1 and CCR2. RNA samples was reverse-transcribed with an oligo(dT)18 (Invitrogen) primer to synthesize cDNA. Reverse-transcription RT-PCR was performed in a Thermal Cycler (Bio-Rad, Hercules, CA, USA). RT-PCR primers were as follows: 18 s: forward, 5'-GATATGCTCATGTG-GTGTTG -3'; reverse, 5'-AATCTTCTTCAGTCGCTCCA-3'; MCP-1: forward, 5'-GATGCAATCAATGCCCCAGT-3'; reverse, 5'-TTGCTTGTCCAGGTGGTCCAT-3'; and CCR2: forward, 5'-CCACATCTCGTTCTCGGTTTATCAG -3'; reverse, 5'-CGTGGAAAATAAGGGCCACAG -3'.
The following conditions were used for RT-PCR amplification: 29 cycles×30 s at 95°C, 45 s at 60°C, and 40 s at 72°C for 18 s; 27 cycles×50 s at 94°C, 1 min at 55°C, and 50 s at 72°C for MCP-1; 31 cycles×9 s at 95°C, 30 s at 64°C, and 25 s at 72°C for CCR2. RT-PCR products were electrophoresed on a 1.5% agarose gel containing 1.0 μg/ml ethidium bromide. Gels were visualized and photographed using image analyzer (Bio-Rad). Samples were assayed in triplicate and 18 s was used as the internal control.
Measurement of NF-κB Activity
NF-κB activity was assessed using TransAM kits (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions. This ELISA-based method is specific, more rapid and sensitive than electrophoretic mobility shift assay and western blot and is better suited for large-scale screening. 16 Briefly, nuclear extracts of treated THP-1 cells were prepared using a nuclear extract kit (Active Motif) according to the manufacturer's protocol. Protein concentrations were determined with BCA protein assay reagents (BiYunTian Biotechnology, Shanghai, China). A total of 10 μg of nuclear extracts was incubated in a 96-well plate immobilized with an oligonucleotide that corresponds to the NF-κB consensus binding site (5'-GGGACTTTCC-3') for 1 h under mild agitation. After washing, wells were incubated with the primary antibodies for p65, p50, c-Rel, p52, and RelB for 1 h. Reactions were visualized by adding anti-IgG horseradish peroxidase conjugate and developing the solution, then quantified at 450 nm with a reference wavelength of 655 nm. The data presented are the result of 4 independent experiments.
Adhesion Assay
Adhesion assays were performed by precoating 96-well plates with 10 μg/ml fibronectin (Sigma) overnight at 4°C followed by gentle washing. Non-specific binding sites were then blocked with 3% bovine serum albumin in serum-free PBS for 1 h at 37°C. Treated THP-1 cells were suspended at a final concentration of 5×10 5 cells/ml. A total of 100 μl cell suspension was then transferred to each precoated well. Plates were incubated in CO2 incubator at 37°C for 1 h. Non-adherent cells were removed with PBS and the remaining cells were calculated using the MTT method. Experiments were performed in duplicate and repeated at least 3 times.
Migration Assay
Monocyte migration was carried out using Transwell chamber with 6.5-mm diameter polycarbonate filters (8 μm pore size; Corning Costar, Cambridge, MA, USA). A total of 100 μl treated THP-1 cell suspensions of 5×10 6 cells/ml in serum-free medium were loaded into the upper chamber, and allowed to migrate for 3 h at 37°C to the lower chamber containing medium with 50 ng/ml recombinant human MCP-1 (Peprotech EC, London, UK) as a chemoattractant. Non-migrating cells on the upper face of the transwell membrane were scraped gently with a cotton swab and washed out with PBS. The migrated cells were fixed with methanol and stained with H&E. The migrated cells were counted on microscopy. Ten fields were counted for each assay. Experiments were performed in duplicate and repeated at least 3 times.
Statistical Analysis
Results are presented as mean ± SEM. Data were analyzed using Student's t-test. P<0.05 was considered significant.
Results
Effects of CRA on Atherosclerotic Lesions
After 12 weeks, morphometric analysis of the aortic valve showed that the wild-type group did not develop lesions but that the atherosclerotic lesion area in the control group was extensive (17.52±2.53%, P<0.001). CRA treatment dramatically reduced the lesion area (11.36±2.51%, P<0.05; Figures 2A,B) .
In accordance with morphometric analysis, quantification analysis with Sudan IV staining showed that the lesion area was significantly reduced by CRA treatment. Quantification of lesion area showed that apoE-deficient mice in the control group developed severe atherosclerotic lesions in the aortic arch (40.11±5.02%, P<0.001) and in the abdominal aorta (46.56±3.57%, P<0.001), both were dramatically reduced in CRA-treated mice (aortic arch, 21.19±2.38%, P<0.005; abdominal aorta, 6.16±2.49%, P<0.001; Figures 2C-F) .
Effects of CRA on Serum Profiles
To find out whether CRA had an effect on serum profiles, several parameters in the serum of mice were investigated. As shown in Table, significant differences were found in the concentration of serum glucose, SOD, MDA and lipids except HDL-C between the apoE-/-and wild-type mice (all P<0.01). CRA treatment tended to lower the serum TG levels (P<0.005), but did not affect serum TC, HDL-C and LDL-C levels. It also caused a significant decrease of serum glucose, MDA and an increase of SOD levels (P<0.001).
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Effects of CRA on MCP-1 Levels in Serum and Aorta Supernatants
To investigate whether CRA attenuates lesion size through effects on MCP-1, we quantified MCP-1 levels in both serum and aortic supernatants. As shown in Figure 3A , in the control group the amount of MCP-1 increased in serum by 1. 
Effects of CRA on mRNA Levels of MCP-1 and CCR2 in the Aorta
To verify the hypothesis that CRA inhibits MCP-1 levels by modulating the mRNA expression of MCP-1, the total RNAs were isolated from the aorta and analyzed on real-time quantitative RT-PCR. In the control group, the mRNA expression of MCP-1 was increased by 3.75-fold (P<0.001) and its receptor CCR2 by 1.26-fold (P<0.01) compared with the wild-type group. As expected, MCP-1 mRNA levels were significantly inhibited by 4.61-fold (P<0.001) in the CRA-fed mice, in keeping with the ELISA findings. Moreover, the mRNA levels of CCR2, the only established functional receptor for MCP-1, were also reduced by 2.08-fold (P<0.001) in CRA-fed mice ( Figure 3B ).
Effects of CRA on Expression of Inflammatory Factors and Transcription Factor in Aortic Endothelium
Because CRA inhibited mRNA levels of MCP-1 and CCR2, immunohistochemical staining for these 2 factors in the aortic endothelium was performed. The immunostaining for MCP-1 and CCR2 was minimal in the wild-type group and maximal in the control group. As expected, CRA regulated immunostaining for MCP-1 and CCR2. The effect of CRA treatment on lesion areas might also be influenced by the presence of adhesion molecules and other chemokines, therefore the immunohistochemical staining for ICAM-1 and IL-8 was also performed. The immunostaining for ICAM-1, IL-8 was strong in the control group but no significant change was found in the CRA-treated group. To determine whether CRA reduces expression of MCP-1 and CCR2 by the NF-κB signaling pathway, the immunoreactivity of NF-κB (p65 subunit) was analyzed. In the wild-type group, low immunoreactivity of NF-κB was found in the cytoplasm, whereas in the control group, a large amount of activated NF-κB was found not only in the cytoplasm but also in the nucleus, suggesting activation of the NF-κB pathway. As expected, in the CRA-treated group this activation was inhibited (Figure 4) .
Effects of CRA on mRNA Levels of MCP-1 and CCR2 in LPS-Induced THP-1 Cells
Because the recruitment of monocytes and their retention within the atherosclerotic lesion contribute to the progression of plaque development, the in vitro experiments were carried out using an LPS-induced THP-1 cell inflammation model. 17, 18 As shown in Figure 5 , on PCR the mRNA levels of MCP-1 and CCR2 were upregulated by LPS (P<0.001). Pretreatment of THP-1 cells with 30 μmol/L and 50 μmol/L CRA significantly blocked the LPS-induced increase of MCP-1 mRNA levels (P<0.001), whereas expression of CCR2 mRNA was not affected.
Effects of CRA on NF-κB Activation in LPS-Induced THP-1 Cells
To gain an insight into whether the inhibitory effect of CRA on LPS-induced MCP-1 mRNA expression is mediated via NF-κB, the activity of 5 protein members of the NF-κB subunit family was measured using an ELISA kit. LPS stimulation significantly increased the amount of activation of the NF-κB family except c-Rel. 
Effects of CRA on Adhesiveness and Migration Capability in LPS-Induced THP-1 Cells
To explore the functional consequences of LPS-induced NF-κB signaling inhibition by CRA, we carried out monocyte adhesion and migration assay. Preincubation with CRA inhibited the stimulating effect of LPS on monocyte adhesiveness ( Figure 7A ) and transwell migration ( Figure 7B ) capability in a dose-dependent manner.
Discussion
Triterpenoids are a large class of isoprenoidal natural products present in higher plants. 19 Among them, ursane-type triterpenes have been reported to exert various pharmacological effects on many diseases, including cancer 20 and atherosclerosis. 2 Our previous study showed that CRA, an ursane-type triterpene, could attenuate atherosclerotic lesion size in LDL receptordeficient mice. The objective of the present study was to explore the molecular mechanisms of the anti-atherosclerosis effect of CRA. The CRA supplementation was shown to significantly ameliorate atherosclerotic lesion development in apoE-/-mice both in the aortic arch and abdominal aorta when compared with the control group. This result supplemented that of the previous study, 2 by using a different animal model and verifying the anti-atherosclerosis effect of CRA. Lipid metabolism is strongly affected by mutation in apoE-/-mice. 21 In contrast to the previous report, 2 we found that CRA did not reduce the level of TC. Moreover, CRA treatment for 12 weeks did not affect serum HDL or LDL levels. The only effect of CRA treatment on serum lipids was a significant decrease in serum TG levels. We suggest that the anti-atherosclerosis effect of CRA in apoE-deficient mice may not only depend on serum lipid level, but also relate to another signaling pathway. CRA also caused a significant decrease of serum glucose, MDA and an increase of SOD levels. These results are consistent with the anti-diabetic and anti-oxidative activities of CRA reported previously. 3, 7 Increased expression of chemokines and adhesion molecules in vascular endothelial cells could be considered as an early sign of the atherogenic process. 22 The present immunohistochemical analysis showed that CRA treatment inhibited the expression of MCP-1 and CCR2 in aortic endothelium, but did not affect IL-8, ICAM-1 expression, indicating that MCP-1/CCR2 is a target of CRA. It has been reported that measurement of circulating MCP-1 may be useful in predicting the risk of atherogenesis. 23 Therefore, we carried out ELISA, which showed that MCP-1 levels in both serum and aorta supernatants were reduced in the CRA group, suggesting that CRA treatment inhibits MCP-1 expression at the local inflamed site as well as peripheral blood circulation. Furthermore, we also found reduced mRNA levels of MCP-1 and CCR2 in the aorta compared with the control mice. We then used an in vitro LPS-induced THP-1 cell inflammation model to verify the downregulating effect of CRA on MCP-1 and CCR2, but the effect was not significant in CCR2 mRNA levels. The functional consequences of CRA on THP-1 cell adhesiveness and migration capability were tested. Because binding of monocytes to fibronectin contributes to monocyte-endothelium interactions, 24 we identified the effects of CRA treatment on monocyte adhesiveness capability by measuring the adhesion of THP-1 cells to fibronectin. Moreover, the effect of CRA on endothelial cell-monocyte interactions were also determined. Results showed that CRA treatment both inhibited the adhesion of monocyte to fibronectin and of endothelial cells to THP-1 (Data S1). The migration assay showed that CRA treatment suppressed the MCP-1-directed migration of THP-1 monocytes. These results support the role of CRA in reducing adhesion and migration of monocytes to the arterial wall, as an early step in atherosclerosis. 25, 26 To further explore the exact mechanisms of CRA in reducing the atherosclerotic lesion areas and mediating MCP-1 expression, we investigated the signal-transduction pathways of CRA. It has recently been reported that CRA might induce tumor apoptosis by both induction of caspase activation and inhibition of STAT3 and NF-κB activation. 27 Given that NF-κB regulates the expression of MCP-1 gene, 28 and is one of the most important pro-inflammatory transcription factors in atherosclerosis, 29,30 it would be reasonable to presume that CRA attenuates atherosclerotic lesions by regulating NF-κB activation. A previous study showed that there was an increase in NF-κB activation, and MCP-1 expression (gene and protein) during development of atherosclerosis. 31 In agreement with that study, the present immunohistochemical analysis showed that apoE-/-mice had increased transcriptional activity of NF-κB and elevated MCP-1 expression in the aortic endothelium, while CRA moderated this abnormality.
Because NF-κB is the main factor involved in the transcription of MCP-1 induced by LPS, 32 we examined transcription factors of the NF-κB family in the LPS-induced THP-1 cell inflammation model. NF-κB consists of complexes of differ-CHEN H et al.
ent combinations of the subunits p65, p50, c-Rel, p52 and Rel B, each with distinct DNA-binding characteristics. 33 NF-κB mediates various activities by changing the relative expression of the various subunits and by changing the formation of specific dimers. The activation of NF-κB is controlled mainly via its nuclear translocation. Previous studies showed that activated NF-κB consists of p65, p50, and c-Rel subunits in human atherosclerotic plaque cells, 34 whereas LPS stimulated translocation of the classical NF-κB components, p50 and p65. 35, 36 In the present study, there is evidence of NF-κB activation in LPS-induced THP-1 cells, in which the nuclei display activated p65, p50, p52 and Rel B. LPS did not significantly affect c-Rel activation but CRA treatment increased the level of activated c-Rel. Because c-Rel is involved in the regulation of apoptosis, 37 the present results support a recent report in which CRA was found to induce apoptosis in HeLa cells. 38 In the meantime, CRA treatment downregulated the LPS-induced activation of p65, which enters the nucleus to initiate transcription of various inflammatory genes. 39 It has been reported that LPS-induced upregulation of p50 is essential for LPS tolerance, 40 therefore the inhibiting effect of CRA on p50 may be due to relief of LPS-induced impairment. Besides, the inhibiting effect of CRA on Rel B may play a role in preventing the initiation of immune responses. 41 In conclusion, we suggest that CRA may exert its anti-atherosclerotic effect via the NF-κB signaling pathway.
In conclusion, the present study has confirmed that CRA treatment (0.3 mg · day -1 · mouse -1 ) could reduce the atherosclerotic lesion areas of apoE-/-mice fed a Western-type diet for 12 weeks. In addition, CRA inhibited monocyte adhesion and migration in LPS-induced THP-1 cells. All of these effects are mediated in part by suppression of the NF-κB signaling pathway.
